PMID- 18404446
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1573-9538 (Print)
IS  - 1573-9546 (Electronic)
IS  - 1573-9538 (Linking)
VI  - 3
IP  - 4
DP  - 2007 Sep
TI  - Adenosine A(2A) receptors modulate BDNF both in normal conditions and in 
      experimental models of Huntington's disease.
PG  - 333-8
LID - 10.1007/s11302-007-9066-y [doi]
AB  - Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, 
      enhances synaptic transmission and regulates neuronal proliferation and survival. 
      Functional interactions between adenosine A(2A) receptors (A(2A)Rs) and BDNF have 
      been recently reported. In this article, we report some recent findings from our 
      group showing that A(2A)Rs regulate both BDNF functions and levels in the brain. 
      Whereas BDNF (10 ng/ml) increased the slope of excitatory postsynaptic field 
      potentials (fEPSPs) in hippocampal slices from wild-type (WT) mice, it was 
      completely ineffective in slices taken from A(2A)R knock-out (KO) mice. 
      Furthermore, enzyme immunoassay studies showed a significant reduction in 
      hippocampal BDNF levels in A(2A)R KO vs. WT mice. Having found an even marked 
      reduction in the striatum of A(2A)R KO mice, and as both BDNF and A(2A)Rs have 
      been implicated in the pathogenesis of Huntington's disease (HD), an inherited 
      striatal neurodegenerative disease, we then evaluated whether the pharmacological 
      blockade of A(2A)Rs could influence striatal levels of BDNF in an experimental 
      model of HD-like striatal degeneration (quinolinic acid-lesioned rats) and in a 
      transgenic mice model of HD (R6/2 mice). In both QA-lesioned rats and early 
      symptomatic R6/2 mice (8 weeks), the systemic administration of the A(2A)R 
      antagonist SCH58261 significantly reduced striatal BDNF levels. These results 
      indicate that the presence and the tonic activation of A(2A)Rs are necessary to 
      allow BDNF-induced potentiation of synaptic transmission and to sustain a normal 
      BDNF tone. The possible functional consequences of reducing striatal BDNF levels 
      in HD models need further investigation.
FAU - Potenza, R L
AU  - Potenza RL
AD  - Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di 
      Sanita, Viale Regina Elena, 299, 00161, Rome, Italy.
FAU - Tebano, M T
AU  - Tebano MT
FAU - Martire, A
AU  - Martire A
FAU - Domenici, M R
AU  - Domenici MR
FAU - Pepponi, R
AU  - Pepponi R
FAU - Armida, M
AU  - Armida M
FAU - Pezzola, A
AU  - Pezzola A
FAU - Minghetti, L
AU  - Minghetti L
FAU - Popoli, P
AU  - Popoli P
LA  - eng
PT  - Journal Article
DEP - 20070915
PL  - Netherlands
TA  - Purinergic Signal
JT  - Purinergic signalling
JID - 101250499
PMC - PMC2072926
EDAT- 2008/04/12 09:00
MHDA- 2008/04/12 09:01
PMCR- 2007/09/01
CRDT- 2008/04/12 09:00
PHST- 2007/06/01 00:00 [received]
PHST- 2007/07/25 00:00 [accepted]
PHST- 2008/04/12 09:00 [pubmed]
PHST- 2008/04/12 09:01 [medline]
PHST- 2008/04/12 09:00 [entrez]
PHST- 2007/09/01 00:00 [pmc-release]
AID - 9066 [pii]
AID - 10.1007/s11302-007-9066-y [doi]
PST - ppublish
SO  - Purinergic Signal. 2007 Sep;3(4):333-8. doi: 10.1007/s11302-007-9066-y. Epub 2007 
      Sep 15.